#United Kingdom #IsomAb #Nottingham #Dr. Brainin #ISM-001

IsomAb Appoints New CEO to Accelerate Development of Revolutionary Angina Treatment

IsomAb Ltd, a biotechnology firm based in the UK, has announced the remarkable appointment of Dr. Philip Brainin as its new Chief Executive Officer (CEO). This move comes at a pivotal time as the company intensifies efforts to advance its innovative therapeutic candidate, ISM-001, a promising treatment for chronic stable angina (CSA). With an estimated 9 million patients affected in the US alone, CSA represents a major unmet medical need, positioning IsomAb for impactful advancements in cardiovascular therapy.

Dr. Brainin's Background and Vision

Dr. Philip Brainin arrives at IsomAb with an impressive background. An accomplished physician-scientist, Dr. Brainin is well-versed in clinical cardiology and has amassed significant experience in both clinical research and venture investing across the United States and European biotechnology industries. His unique combination of expertise positions him perfectly to lead IsomAb as it prepares to transition ISM-001 into clinical development.

Dr. Brainin has been actively involved in various early-stage therapeutic companies, guiding boards of directors and shaping corporate strategies for successful financing and partnerships. His extensive knowledge in cardiovascular medicine fuels his passion for innovation at IsomAb, where he perceives a lack of effective therapeutic options for patients suffering from ischemic diseases.

“With my background in cardiology, I see every day how limited our options are for patients with ischemic disease,” stated Dr. Brainin. “What excites me about IsomAb is that ISM-001 is not just another VEGF therapy. This pioneering data shows that IsomAb's approach targets VEGF-A165b, effectively unlocking angiogenesis, which is crucial for restoring blood flow.”

ISM-001: A Game-Changer for Patients

Developed by IsomAb, ISM-001 stands out as a high-affinity, humanized antibody designed to restore blood circulation in ischemic tissues. The therapy aims to provide a disease-modifying treatment for chronic stable angina, which is often inadequately addressed by existing medical options. Preclinical studies have demonstrated that ISM-001 can lead to the complete restoration of blood flow in severe ischemic disease models, creating optimism for patients and healthcare professionals alike.

Dr. Brainin's leadership will guide the company through critical phases of clinical trials and development, ensuring that IsomAb can maximize the therapeutic potential of ISM-001. Strong preclinical results pave the way as the company gears up for a Series A fundraising notably bolstered by its solid translational plan and successful preclinical outcomes.

New Leadership Structure

Joining Dr. Brainin in this revolutionary journey is Dr. Anker Lundemose, who has stepped in as the Chair of the Board of Directors, succeeding Paul Edwards, who will continue as a non-executive director. Dr. Lundemose brings extensive experience from previous positions at leading biotech firms and embodies a successful track record in fostering exceptional investor exits through mergers, acquisitions, and public offerings.

“With Philip’s appointment and our promising preclinical outcomes, IsomAb presents an exciting Series A investment opportunity,” remarked Dr. Lundemose. “Our goal is to accelerate ISM-001’s development into a breakthrough therapy for cardiovascular disease.”

About IsomAb Ltd

Founded in 2022 and emerging as a spinout from the esteemed University of Nottingham, IsomAb Ltd is dedicated to developing isoform-specific antibody therapies targeting life-threatening conditions such as chronic stable angina. This innovative firm was established by Professors David Bates and Steve Harper, who have been instrumental in groundbreaking research into neurology and cardiovascular health. Supported by illustrious organizations such as the British Heart Foundation, Wellcome Trust, and the Medical Research Council, IsomAb is poised to make significant contributions to the biopharmaceutical landscape.

For more information about IsomAb and its groundbreaking work in cardiovascular therapeutic approaches, visit IsomAb's website.

As IsomAb steps into this exciting new chapter under Dr. Brainin's leadership, the biopharmaceutical community will be closely watching its advancements in getting ISM-001 ready for clinical testing. With the dawn of innovative solutions on the horizon, the future of ischemic disease treatment may soon look brighter than ever.